» Articles » PMID: 37414199

Targeting of HBP1/TIMP3 Axis As a Novel Strategy Against Breast Cancer

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2023 Jul 6
PMID 37414199
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant proliferation and metastasis are the main causes of breast cancer death. The transcription factor high mobility group (HMG) box-containing protein 1 (HBP1) is an important tumor suppressor whose deletion or mutation is closely related to the appearance of tumors. Here, we investigated the role of HBP1 in breast cancer suppression. HBP1 enhances the activity of the tissue inhibitors of metalloproteinases 3 (TIMP3) promoter, thereby increasing protein and mRNA levels of TIMP3. TIMP3 increases the phosphatase and tensin homolog (PTEN) protein level by inhibiting its degradation and acts as a metalloproteinase inhibitor to inhibit the protein levels of MMP2/9. In this study, we demonstrated that the HBP1/TIMP3 axis plays a crucial role in inhibiting the tumorigenesis of breast cancer. HBP1 deletion interferes with the regulation of the axis and induces the occurrence and malignant progression of breast cancer. In addition, the HBP1/TIMP3 axis promotes the sensitivity of breast cancer to radiation therapy and hormone therapy. Our study opens new perspectives on the treatment and prognosis of breast cancer.

Citing Articles

LINC00899 suppresses the progression of triple-negative breast cancer via the miRNA-425/PTEN axis and is a biomarker for neoadjuvant chemotherapy efficacy.

Niu L, Bai Y, Yu M, Sun X J Cancer. 2025; 16(5):1647-1655.

PMID: 39991583 PMC: 11843232. DOI: 10.7150/jca.100619.


Adipose mesenchymal stem cell conditioned medium and extract: A promising therapeutic option for regenerative breast cancer therapy.

Kazemi F, Sadeghian F, Pirsadeghi A, Asadi F, Javdani H, Yousefi-Ahmadipour A SAGE Open Med. 2024; 12:20503121241306606.

PMID: 39691866 PMC: 11650577. DOI: 10.1177/20503121241306606.


Long-Term Effect of TIMP3 Gene Expression on Thyroid Cancer: A Cure Model Analysis.

Dindarloo M, Fendereski A, Kashi Z, Yazdani-Charati J Asian Pac J Cancer Prev. 2024; 25(10):3627-3634.

PMID: 39471030 PMC: 11711355. DOI: 10.31557/APJCP.2024.25.10.3627.


Estrogen receptor alpha (ERα) regulates PARN-mediated nuclear deadenylation and gene expression in breast cancer cells.

Varriano S, Yu A, Xu Y, Natelson D, Ramadei A, Kleiman F RNA Biol. 2024; 21(1):14-23.

PMID: 39392174 PMC: 11487348. DOI: 10.1080/15476286.2024.2413821.


Reclassify High-Grade Serous Ovarian Cancer Patients Into Different Molecular Subtypes With Discrepancy Prognoses and Therapeutic Responses Based on Cancer-Associated Fibroblast-Enriched Prognostic Genes.

Liu X, Ping G, Ji D, Wen Z, Chen Y Biomed Eng Comput Biol. 2024; 15:11795972241274024.

PMID: 39221174 PMC: 11365035. DOI: 10.1177/11795972241274024.